SELLAS Life Sciences (SLS) closed at $9.68 on Oct 30, 2026, down 4.7% on the day. The stock is down 14.6% over the past month, down 13.7% over three months, up 156.8% year to date and up 365.4% over the past year. It trades 39.0% below its 52-week high of $15.88 and 596.4% above its 52-week low of $1.39. The close sits below its 50-day moving average ($12.16) and above its 200-day moving average ($8.57).
Over its last 8 reports the stock moved an average of 7.6% on the first trading day after earnings, beating the options-implied move in 2 of 5.
Up 406% in one year, the SLS do-or-die game now has only one piece of data left
No revenue but worth $1.95 billion—REGAL's top-line results this quarter are revealed, with tight valuations and a binary outcome.
Oct 30, 2026
Over the last 8 reports, SLS moved an average of 7.6% on the first trading day after earnings. The move beat the options-implied move in 2 of 5 reports.
Yes — the Oct 30, 2026 close of $9.68 is 12.9% above the 200-day average of $8.57.
SLS closed 39.0% below its 52-week high of $15.88.
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
